Dillon Voss

Dillon M. VossImage: Dillon Voss


B.S. California University of Pennsylvania (2013)

M.S. Case Western Reserve University (2017)

Current Position:

3rd Year MSTP

1st Year Grad Student


Adrian Krainer, CSHL

Graduate Program:


Research Interest:

My broad research interests include studying how the tumor microenvironment alters and maintains cancer stem cell (CSC) signaling pathways, as well as integrating omics-driven research with bioinformatics to improve how tumors are characterized and treated. My previous work mainly involved studying the hypoxic tumor microenvironment of high-grade gliomas, and identifying small molecule compounds that disrupted various signaling nodes of common CSC maintenance pathways. I look forward to developing a more translational approach to my research, with hopes to both assist cancer patients as they navigate clinical trials, as well as use these experiences to guide my search for new therapies.  


Voss, DM, Sloan  A, Spina R, Ames HM & Bar EE. The Alternative Splicing Factor MBNL1 Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness. Cancer Research (2020).

Spina R, Voss DM, Yang X, et al. MCT4 regulates de novo pyrimidine biosynthesis in GBM in a lactate-independent manner. Neurooncol Adv. 2020;2(1):vdz062. doi:10.1093/noajnl/vdz062

Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ, Bar EE. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Scientific Reports. 2017;7:4292. doi:10.1038/s41598-017-04612-w.

Spina R, Voss DM, Asnaghi L, Sloan A, Bar EE. Flow Cytometry-Based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells. (In press – Journal of Visualized Experiments).

Spina R, Voss DM, Asnaghi L, Sloan A, Bar EE. Atracurium Besylate and Other Neuromuscular Blocking Agents Promote Astroglial Differentiation and Deplete Glioblastoma Stem Cells. Oncotarget. 2016 Jan 5;7(1):459-72. doi: 10.18632/oncotarget.6314.